Article

Genetic evidence for serum amyloid P component as a drug target for treatment of neurodegenerative disorders

2023-08-16

Abstract excerpt

The direct causes of neurodegeneration underlying Alzheimer’s disease (AD) and many other dementias, are not known. Here we identify serum amyloid P component (SAP), a constitutive plasma protein normally excluded from the brain, as a potential drug target. After meta-analysis of three genome-wide association studies, comprising 44,288 participants, cis -Mendelian randomization showed that genes responsible for hi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 24b8b244-55ea-5dee-a4ed-2345780a878c
DOI: 10.1101/2023.08.15.23293564

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Genetic evidence for serum amyloid P component as a drug target for treatment of neurodegenerative disordersDOI 10.1101/2023.08.15.23293564Read

Genetic evidence for serum amyloid P component as a drug target in neurodegenerative disorders.Semantic proximity Read

Identification of potential therapeutic targets for Alzheimer's disease from the proteomes of plasma and cerebrospinal fluid in a multicenter Mendelian randomization studySemantic proximity Read

A genome-wide association meta-analysis of plasma Aβ peptides concentrations in the elderly.Semantic proximity Read

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assaySemantic proximity Read

Amyloid, tau and risk of Alzheimer's disease: a Mendelian randomization study.Semantic proximity Read

Gene-variant specific effects of plasma amyloid-β levels in Swedish autosomal dominant Alzheimer disease.Semantic proximity Read

Associations between genetically predicted plasma protein levels and Alzheimer’s disease risk: a study using genetic prediction modelsSemantic proximity Read

Blood-derived amyloid-β protein induces Alzheimer’s disease pathologiesSemantic proximity Read

Beyond amyloid: Immune, cerebrovascular, and metabolic contributions to Alzheimer disease in people with Down syndromeSemantic proximity Read

Abnormal Amyloidogenesis Identified in Plasma of Patients with Spinocerebellar Ataxia Type 12.Semantic proximity Read

Definition of a threshold on the plasma Aβ42/Aβ40 ratio measured by single-molecule array to predict the amyloid status of individuals without dementiaSemantic proximity Read

Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy.Semantic proximity Read